Isabel Fofana1,2, Samira Fafi-Kremer1,2,3, Patric Carolla1,2, Catherine Fauvelle1,2, Muhammad Nauman Zahid1,2, Marine Turek1,2, Laura Heydmann1,2, Karine Cury1,2, Juliette Hayer4, Christophe Combet4, François-Loïc Cosset5, Thomas Pietschmann6, Marie-Sophie Hiet7, Ralf Bartenschlager7, François Habersetzer1,2,8, Michel Doffoël1,2,8, Zhen-Yong Keck9, Steven K H Foung9, Mirjam B Zeisel1,2, Françoise Stoll-Keller1,2,3, Thomas F Baumert1,2,8. 1. Inserm, U748, Strasbourg, France. 2. Université de Strasbourg, Strasbourg, France. 3. Laboratoire de Virologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France. 4. Bases Moléculaires et Structurales des Systèmes Infectieux, UMR 5086, Centre National de la Recherche Scientifique, Université de Lyon, Institut de Biologie et Chimie des Proteines, Lyon, France. 5. Université de Lyon, Université Claude Bernard Lyon1, IFR 128, Inserm U758; Ecole Normale Supérieure de Lyon, 69364 Lyon, France. 6. Division of Experimental Virology, TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture between the Medical School Hannover and the Helmholtz Centre for Infection Research, Hannover, Germany. 7. The Department of Infectious Diseases, Molecular Virology, Heidelberg University, Heidelberg, Germany. 8. Pôle Hepato-Digestif, Hôpitaux Universitaires de Strasbourg, Strasbourg, France. 9. Department of Pathology, Stanford University School of Medicine, Stanford, California.
Abstract
BACKGROUND & AIMS: The development of vaccines and other strategies to prevent hepatitis C virus (HCV) infection is limited by rapid viral evasion. HCV entry is the first step of infection; this process involves several viral and host factors and is targeted by host-neutralizing responses. Although the roles of host factors in HCV entry have been well characterized, their involvement in evasion of immune responses is poorly understood. We used acute infection of liver graft as a model to investigate the molecular mechanisms of viral evasion. METHODS: We studied factors that contribute to evasion of host immune responses using patient-derived antibodies, HCV pseudoparticles, and cell culture-derived HCV that express viral envelopes from patients who have undergone liver transplantation. These viruses were used to infect hepatoma cell lines that express different levels of HCV entry factors. RESULTS: By using reverse genetic analyses, we identified altered use of host-cell entry factors as a mechanism by which HCV evades host immune responses. Mutations that alter use of the CD81 receptor also allowed the virus to escape neutralizing antibodies. Kinetic studies showed that these mutations affect virus-antibody interactions during postbinding steps of the HCV entry process. Functional studies with a large panel of patient-derived antibodies showed that this mechanism mediates viral escape, leading to persistent infection in general. CONCLUSIONS: We identified a mechanism by which HCV evades host immune responses, in which use of cell entry factors evolves with escape from neutralizing antibodies. These findings advance our understanding of the pathogenesis of HCV infection and might be used to develop antiviral strategies and vaccines.
BACKGROUND & AIMS: The development of vaccines and other strategies to prevent hepatitis C virus (HCV) infection is limited by rapid viral evasion. HCV entry is the first step of infection; this process involves several viral and host factors and is targeted by host-neutralizing responses. Although the roles of host factors in HCV entry have been well characterized, their involvement in evasion of immune responses is poorly understood. We used acute infection of liver graft as a model to investigate the molecular mechanisms of viral evasion. METHODS: We studied factors that contribute to evasion of host immune responses using patient-derived antibodies, HCV pseudoparticles, and cell culture-derived HCV that express viral envelopes from patients who have undergone liver transplantation. These viruses were used to infect hepatoma cell lines that express different levels of HCV entry factors. RESULTS: By using reverse genetic analyses, we identified altered use of host-cell entry factors as a mechanism by which HCV evades host immune responses. Mutations that alter use of the CD81 receptor also allowed the virus to escape neutralizing antibodies. Kinetic studies showed that these mutations affect virus-antibody interactions during postbinding steps of the HCV entry process. Functional studies with a large panel of patient-derived antibodies showed that this mechanism mediates viral escape, leading to persistent infection in general. CONCLUSIONS: We identified a mechanism by which HCV evades host immune responses, in which use of cell entry factors evolves with escape from neutralizing antibodies. These findings advance our understanding of the pathogenesis of HCV infection and might be used to develop antiviral strategies and vaccines.
Authors: K G Hadlock; R E Lanford; S Perkins; J Rowe; Q Yang; S Levy; P Pileri; S Abrignani; S K Foung Journal: J Virol Date: 2000-11 Impact factor: 5.103
Authors: Luke Uebelhoer; Jin-Hwan Han; Benoit Callendret; Guaniri Mateu; Naglaa H Shoukry; Holly L Hanson; Charles M Rice; Christopher M Walker; Arash Grakoui Journal: PLoS Pathog Date: 2008-09-05 Impact factor: 6.823
Authors: Eva Dazert; Christoph Neumann-Haefelin; Stéphane Bressanelli; Karen Fitzmaurice; Julia Kort; Jörg Timm; Susan McKiernan; Dermot Kelleher; Norbert Gruener; John E Tavis; Hugo R Rosen; Jaqueline Shaw; Paul Bowness; Hubert E Blum; Paul Klenerman; Ralf Bartenschlager; Robert Thimme Journal: J Clin Invest Date: 2009-01-12 Impact factor: 14.808
Authors: Jan M Pestka; Mirjam B Zeisel; Edith Bläser; Peter Schürmann; Birke Bartosch; Francois-Loïc Cosset; Arvind H Patel; Helga Meisel; Jens Baumert; Sergei Viazov; Kay Rispeter; Hubert E Blum; Michael Roggendorf; Thomas F Baumert Journal: Proc Natl Acad Sci U S A Date: 2007-03-28 Impact factor: 11.205
Authors: Chaturaka Rodrigo; Melanie R Walker; Preston Leung; Auda A Eltahla; Jason Grebely; Gregory J Dore; Tanya Applegate; Kimberly Page; Sunita Dwivedi; Julie Bruneau; Meghan D Morris; Andrea L Cox; William Osburn; Arthur Y Kim; Janke Schinkel; Naglaa H Shoukry; Georg M Lauer; Lisa Maher; Margaret Hellard; Maria Prins; Fabio Luciani; Andrew R Lloyd; Rowena A Bull Journal: Infect Genet Evol Date: 2017-01-05 Impact factor: 3.342
Authors: Brian G Pierce; Zhen-Yong Keck; Patrick Lau; Catherine Fauvelle; Ragul Gowthaman; Thomas F Baumert; Thomas R Fuerst; Roy A Mariuzza; Steven K H Foung Journal: Proc Natl Acad Sci U S A Date: 2016-10-26 Impact factor: 11.205
Authors: R T Chung; F D Gordon; M P Curry; T D Schiano; S Emre; K Corey; J F Markmann; M Hertl; J J Pomposelli; E A Pomfret; S Florman; M Schilsky; T J Broering; R W Finberg; G Szabo; P D Zamore; U Khettry; G J Babcock; D M Ambrosino; B Leav; M Leney; H L Smith; D C Molrine Journal: Am J Transplant Date: 2013-01-28 Impact factor: 8.086
Authors: Vedashree Ramakrishnaiah; Christine Thumann; Isabel Fofana; Francois Habersetzer; Qiuwei Pan; Petra E de Ruiter; Rob Willemsen; Jeroen A A Demmers; Victor Stalin Raj; Guido Jenster; Jaap Kwekkeboom; Hugo W Tilanus; Bart L Haagmans; Thomas F Baumert; Luc J W van der Laan Journal: Proc Natl Acad Sci U S A Date: 2013-07-22 Impact factor: 11.205